Board & Management
The CSL Board is responsible for oversight of the management of the Company and providing strategic direction.
Global Leadership Group is responsible for the day to day running of CSL.
CSL Board Members
Professor John Shine|
Chief Executive Officer
and Managing Director
| || || || || |
Ed Bailey|| |
| || || || || |
John Shine, AOBSc (Hon), PhD, DSc, FAA – (Age 69)Pharmaceutical Industry and Medicine (resident in NSW)
Professor Shine was appointed to the CSL Board in June 2006 and became Chairman in October 2011. He is Professor of Molecular Biology and Professor of Medicine at the University of NSW, and a Director of many scientific research and medical bodies throughout Australia. Professor Shine is President of the Museum of Applied Arts and Science (Powerhouse Museum and Sydney Observatory) and was formerly Executive Director of the Garvan Institute of Medical Research. He was also formerly Chairman of the National Health and Medical Research Council and a Member of the Prime Minister’s Science, Engineering and Innovation Council. In November 2010, he was awarded the 2010 Prime Minister’s Prize for Science.Professor Shine is Chairman of the Nomination Committee and a member of the Innovation and Development Committee.
Paul PerreaultBA Psychology – (Age 58)International Pharmaceutical Industry (resident in US)
Chief Executive Officer and Managing Director
Paul Perreault was appointed to the CSL Board in February 2013 and was appointed as the Chief Executive Officer and Managing Director in July 2013. Paul joined a CSL predecessor company in 1997 and has held senior roles in sales, marketing and operations with his most recent prior position being President, CSL Behring. He has also worked in senior leadership roles with Wyeth, Centeon, Aventis Bioservices and Aventis Behring. Paul was previously Chairman of the Global Board for the Plasma Protein Therapeutics Association. He has had more than 30 years' experience in the global healthcare industry.
Mr Perreault is a member of the Innovation and Development Committee.
John AkehurstMA (Oxon), FIMechE – (Age 66)
Engineering and Management (resident in Western Australia)
Mr Akehurst was appointed to the CSL Board in April 2004. He had 30 years’ executive experience in the international hydrocarbon industry, including seven years as Managing Director and CEO of Woodside Petroleum Ltd. Mr Akehurst is a member of the Board of the Reserve Bank of Australia and is a Director of Origin Energy Limited, and Transform Exploration Pty Ltd. He was formerly Chairman of Alinta Limited and of Coogee Resources Limited and is a former Director of Oil Search Limited. Mr Akehurst is Chairman of the National Centre for Asbestos Related Diseases and the Fortitude Foundation.Mr Akehurst is Chairman of the Human Resources and Remuneration Committee and a member of the Nomination Committee.
David AnsticeBEc – (Age 67)International Pharmaceutical Industry (resident in Pennsylvania, US)
Mr Anstice was appointed to the CSL Board in September 2008. He was a long-time member of the Board of Directors and Executive Committee of the US Biotechnology Industry Organisation, and has over 45 years’ experience in the global pharmaceutical industry. Until his retirement in August 2008, Mr Anstice was for many years a senior executive of Merck & Co., Inc., serving at various times as President of Human Health for US/Canada/Latin America, Europe and Asia, and at retirement was an Executive Vice President. He is a Director of Alkermes Plc, Dublin, Ireland, and a Director of the United States Studies Centre at the University of Sydney.Mr Anstice is a member of the Human Resources and Remuneration Committee, the Innovation and Development Committee and the Nomination Committee.
Bruce BrookBCom, BAcc, FCA, MAICD – (Age 60)
Finance and Management (resident in Victoria)
Mr Brook was appointed to the CSL Board in August 2011. He is currently Chairman of Programmed Maintenance Services Limited and a Director of Newmont Mining Corporation. Mr Brook has previously been Chairman of Energy Developments Limited and a Director of Boart Longyear Limited, Lihir Gold Limited and Consolidated Minerals Limited. During his executive career he was Chief Financial Officer of WMC Resources Limited and prior to that the Deputy Chief Financial Officer of the ANZ Banking Group.Mr Brook is Chairman of the Audit and Risk Management Committee and a member of the Nomination Committee.
Marie McDonaldBSc (Hon), LLB (Hon) – (Age 59)
Law (resident in Victoria)
Ms McDonald was appointed to the CSL Board in August 2013. For many years she has practised in company and commercial law and she was a partner of Ashurst (formerly Blake Dawson) until July 2014. Ms McDonald was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia from 2012 to 2013, having previously been the Deputy Chair, and was also a member of the Australian Takeovers Panel from 2001 to 2010.Ms McDonald is a member of the Audit and Risk Management Committee and the Nomination Committee.
Christine O’ReillyBBus – (Age 54)
Finance and Infrastructure (resident in Victoria)
Ms O’Reilly was appointed to the CSL Board in February 2011. She is a Director of the Transurban Group, Energy Australia, Medibank Private Limited, Baker IDI and Deputy Chair of Care Australia. Christine has in excess of 30 years financial and operational business experience in domestic and off-shore organisations. During her executive career, she was Co-Head of Unlisted Infrastructure Investments at Colonial First State Global Asset Management and prior to that was the Chief Executive Offi cer of the GasNet Australia Group.Ms O’Reilly is a member of the Audit and Risk Management Committee, the Human Resources and Remuneration Committee, and the Nomination Committee.
Maurice RenshawB.Pharm – (Age 68)International Pharmaceutical Industry (resident in NSW)
Mr Renshaw was appointed to the CSL Board in July 2004. Formerly, he was Vice President of Pfizer Inc, USA, Executive Vice President, Pfizer Global Consumer Group and President of Pfizer’s Global Consumer Healthcare Division. Prior to his positions in Pfizer, Mr Renshaw was Vice President of Warner Lambert Co. and President of Parke-Davis USA. He has had more than 35 years’ experience in the global pharmaceutical industry with responsibility for R&D, Manufacturing, Finance, marketing and General Management across Europe, the US and Asia including Japan and China.Mr Renshaw is Chairman of the Innovation and Development Committee and a member of the Nomination Committee.
Edward BaileyLLB, B.Com, FGIA – (Age 49)